Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Eur J Clin Invest ; 53(1): e13881, 2023 Jan.
Article in English | MEDLINE | ID: mdl-36169086

ABSTRACT

BACKGROUND: The efficacy and safety of high versus medium doses of glucocorticoids for the treatment of patients with COVID-19 has shown mixed outcomes in controlled trials and observational studies. We aimed to evaluate the effectiveness of methylprednisolone 250 mg bolus versus dexamethasone 6 mg in patients with severe COVID-19. METHODS: A randomised, open-label, controlled trial was conducted between February and August 2021 at four hospitals in Spain. The trial was suspended after the first interim analysis since the investigators considered that continuing the trial would be futile. Patients were randomly assigned in a 1:1 ratio to receive dexamethasone 6 mg once daily for up to 10 days or methylprednisolone 250 mg once daily for 3 days. RESULTS: Of the 128 randomised patients, 125 were analysed (mean age 60 ± 17 years; 82 males [66%]). Mortality at 28 days was 4.8% in the 250 mg methylprednisolone group versus 4.8% in the 6 mg dexamethasone group (absolute risk difference, 0.1% [95% CI, -8.8 to 9.1%]; p = 0.98). None of the secondary outcomes (admission to the intensive care unit, non-invasive respiratory or high-flow oxygen support, additional immunosuppressive drugs, or length of stay), or prespecified sensitivity analyses were statistically significant. Hyperglycaemia was more frequent in the methylprednisolone group at 27.0 versus 8.1% (absolute risk difference, -18.9% [95% CI, -31.8 to - 5.6%]; p = 0.007). CONCLUSIONS: Among severe but not critical patients with COVID-19, 250 mg/d for 3 days of methylprednisolone compared with 6 mg/d for 10 days of dexamethasone did not result in a decrease in mortality or intubation.


Subject(s)
COVID-19 , Adult , Male , Humans , Middle Aged , Aged , Methylprednisolone , SARS-CoV-2 , Dexamethasone , Treatment Outcome
2.
PLoS One ; 16(4): e0240200, 2021.
Article in English | MEDLINE | ID: mdl-33882060

ABSTRACT

BACKGROUND: Efficient and early triage of hospitalized Covid-19 patients to detect those with higher risk of severe disease is essential for appropriate case management. METHODS: We trained, validated, and externally tested a machine-learning model to early identify patients who will die or require mechanical ventilation during hospitalization from clinical and laboratory features obtained at admission. A development cohort with 918 Covid-19 patients was used for training and internal validation, and 352 patients from another hospital were used for external testing. Performance of the model was evaluated by calculating the area under the receiver-operating-characteristic curve (AUC), sensitivity and specificity. RESULTS: A total of 363 of 918 (39.5%) and 128 of 352 (36.4%) Covid-19 patients from the development and external testing cohort, respectively, required mechanical ventilation or died during hospitalization. In the development cohort, the model obtained an AUC of 0.85 (95% confidence interval [CI], 0.82 to 0.87) for predicting severity of disease progression. Variables ranked according to their contribution to the model were the peripheral blood oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio, age, estimated glomerular filtration rate, procalcitonin, C-reactive protein, updated Charlson comorbidity index and lymphocytes. In the external testing cohort, the model performed an AUC of 0.83 (95% CI, 0.81 to 0.85). This model is deployed in an open source calculator, in which Covid-19 patients at admission are individually stratified as being at high or non-high risk for severe disease progression. CONCLUSIONS: This machine-learning model, applied at hospital admission, predicts risk of severe disease progression in Covid-19 patients.


Subject(s)
COVID-19/classification , Machine Learning , Adult , Aged , Area Under Curve , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/therapy , Cohort Studies , Female , Forecasting , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Models, Statistical , ROC Curve , Respiration, Artificial , Retrospective Studies , Risk Assessment , SARS-CoV-2/isolation & purification , Severity of Illness Index , Spain/epidemiology , Triage/methods
3.
Eur Psychiatry ; 24(3): 191-4, 2009 Apr.
Article in English | MEDLINE | ID: mdl-18849153

ABSTRACT

BACKGROUND: Fyn tyrosine kinase is a member of the Scr family that phosphorylates the NR2A and NR2B subunits of the NMDA receptors reducing the inhibitory effects of ethanol and therefore may regulate the individual sensitivity to ethanol. OBJECTIVES: To investigate whether there is any relationship between the polymorphism at position -93 of the Fyn kinase gene and the susceptibility to develop alcoholism. METHODS: We studied the distribution of genotypes and alleles of the polymorphism -93A/G (137346 T/C) in the 5' UTR region of the fyn gene in 207 male heavy drinkers (119 with alcohol dependence and 88 with alcohol abuse) and 100 control subjects from Castilla y León (Spain). RESULTS: The frequency of G allele carriers was higher in alcohol dependents than in alcohol abusers (47.9% vs 30.6%; p=0.015; OR=2.077; 95% CI 1.165-3.704). CONCLUSION: Our results show that the -93G allele of Fyn kinase gene is associated with higher risk to develop alcohol dependence in Spanish men.


Subject(s)
Alcoholism/genetics , Genetic Predisposition to Disease/genetics , Polymorphism, Genetic/genetics , Proto-Oncogene Proteins c-fyn/genetics , White People/genetics , Adult , Aged , Alcoholism/metabolism , Alleles , Chromosome Mapping , Gene Frequency , Genome-Wide Association Study , Genotype , Humans , Male , Middle Aged , Proto-Oncogene Proteins c-fyn/metabolism , Receptors, N-Methyl-D-Aspartate/genetics , Receptors, N-Methyl-D-Aspartate/metabolism , Spain/ethnology
4.
Curr HIV Res ; 6(2): 164-70, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18336264

ABSTRACT

Adherence to highly active antiretroviral therapy (HAART) has been scarcely studied in correctional settings. Our study aims to evaluate the relationship between adherence and virological outcome and to determine factors related to adherence in correctional settings. A cross-sectional retrospective study was performed in Topas prison (Salamanca, Spain). 50 inmates starting HAART were studied. Adherence was estimated through a self-report questionnaire and variables related to adherence (covering individual factors, the illness itself and the therapeutic regimen) were recorded. HIV-RNA levels and CD4 lymphocyte count were measured before starting therapy and six months after. Statistical analysis was performed using univariate and multivariate methods. 21 inmates (42%) were considered adherent and 29 (58%) were non-adherent. Adherence to treatment, as measured by our questionnaire, was the only significant and independent factor associated with an undetectable viral load at six months of therapy. Five variables were significantly associated with adherence to treatment, four of them as predictor factors for good adherence: an active occupation inside prison, the absence of HIV-related symptoms, a good or average acceptance of treatment, and a higher academic background; previous injection drug use as a risk factor for HIV transmission was associated with non-adherence. A simple self-report questionnaire may be useful for assessing adherence in prison inmates. Recognizing variables associated with adherence is essential to identify prisoners at high risk of being non-adherents in order to develop strategies for improving compliance.


Subject(s)
Antiretroviral Therapy, Highly Active , HIV Infections/drug therapy , Patient Compliance/statistics & numerical data , Adult , CD4 Lymphocyte Count , Cross-Sectional Studies , Female , HIV Infections/immunology , HIV Infections/virology , Humans , Male , Middle Aged , Prisons , RNA, Viral/blood , Retrospective Studies , Risk Factors , Spain , Surveys and Questionnaires , Treatment Outcome , Treatment Refusal , Viral Load
5.
Curr HIV Res ; 4(2): 221-7, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16611060

ABSTRACT

BACKGROUND: Multiple factors have been previously described which could influence adherence to HAART. Our objective is to determine the fundamental factors which influence adherence to highly active antiretroviral therapy in our population. METHODS: A cross-sectional study was made selecting 143 outpatients attending our hospital HIV unit. 22 factors were recorded which could influence adherence to treatment (covering individual factors, the illness itself, the therapeutic regimen and the medical team). Adherence was estimated by the combination of two methods (self-report and pharmacy data); statistical analysis was performed using univariate and multivariate methods. RESULTS: 96 patients (67.13%) had good adherence and 47 (32.87%) did not. Only 3 of the 22 factors studied were significant and independent factors related with adherence: employment, housing situation and degree of treatment acceptance. CONCLUSIONS: we have found some differences regarding HAART adherence in our population compared with previous studies. Psychosocial and behavioral factors were the principal ones. We must try to detect patients at high risk of non-adherence in order to take therapeutic decisions properly, try to reinforce adherence and modify the factors associated with poor adherence.


Subject(s)
Anti-HIV Agents/administration & dosage , Antiretroviral Therapy, Highly Active , HIV Infections/drug therapy , HIV/growth & development , Patient Compliance , Adult , Cross-Sectional Studies , Female , Health Behavior , Humans , Male , Multivariate Analysis , Spain , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...